Nuveen LLC Acquires Shares of 96,808 Prestige Consumer Healthcare Inc. $PBH

Key Points

• Nuveen LLC has acquired a new stake in Prestige Consumer Healthcare Inc., purchasing 96,808 shares valued at approximately $8.32 million.
• Prestige Consumer Healthcare's recent quarterly earnings report revealed earnings per share of $0.95, which missed analysts' expectations of $1.01.
• Research analysts have issued mixed ratings for the stock, with three maintaining a Buy rating and three offering a Hold rating, while the average price target is set at $93.33.

Nuveen LLC acquired a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 96,808 shares of the company's stock, valued at approximately $8,323,000. Nuveen LLC owned approximately 0.20% of Prestige Consumer Healthcare at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Opal Wealth Advisors LLC purchased a new stake in shares of Prestige Consumer Healthcare during the first quarter worth approximately $38,000. McIlrath & Eck LLC increased its position in shares of Prestige Consumer Healthcare by 19.1% during the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock worth $75,000 after purchasing an additional 154 shares in the last quarter. Johnson Financial Group Inc. purchased a new stake in shares of Prestige Consumer Healthcare during the fourth quarter worth approximately $93,000. Costello Asset Management INC purchased a new stake in shares of Prestige Consumer Healthcare during the first quarter worth approximately $112,000. Finally, Tower Research Capital LLC TRC increased its position in shares of Prestige Consumer Healthcare by 97.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,925 shares of the company's stock worth $150,000 after purchasing an additional 950 shares in the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Stock Up 0.6%

Shares of PBH stock traded up $0.41 during trading hours on Thursday, reaching $67.37. 361,921 shares of the stock were exchanged, compared to its average volume of 395,860. The business's fifty day moving average is $74.26 and its two-hundred day moving average is $80.83. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99. Prestige Consumer Healthcare Inc. has a 12-month low of $62.95 and a 12-month high of $90.04. The firm has a market capitalization of $3.32 billion, a P/E ratio of 15.80, a P/E/G ratio of 2.10 and a beta of 0.43.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing analysts' consensus estimates of $1.01 by ($0.06). The firm had revenue of $249.53 million for the quarter, compared to analysts' expectations of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The firm's quarterly revenue was down 6.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.90 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. As a group, research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on PBH. Wall Street Zen downgraded Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Canaccord Genuity Group dropped their target price on Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Finally, Royal Bank Of Canada raised Prestige Consumer Healthcare to a "hold" rating in a research report on Thursday, May 8th. Three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of "Moderate Buy" and an average price target of $93.33.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.